Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas

Trial Profile

Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant thymoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2017 Protocol amended with addition of Epacadostat and time frame of secondary endpoint revised.
    • 26 Oct 2017 Planned number of patients changed from 17 to 67.
    • 26 Oct 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top